About Thryv Therapeutics
Thryv Therapeutics is a company based in Montreal (Canada) founded in 2018.. Thryv Therapeutics has raised $24 million across 3 funding rounds from investors including ARE, EJP RD and Invest Quebec. Thryv Therapeutics offers products and services including SGK1 Inhibitors and THRV-1268. Thryv Therapeutics operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Incyte and argenx, among others.
- Headquarter Montreal, Canada
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Thryv Therapeutics Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$24 M (USD)
in 3 rounds
-
Latest Funding Round
$5 M (USD), Series A
Jun 06, 2023
-
Investors
ARE
& 6 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Thryv Therapeutics
Thryv Therapeutics offers a comprehensive portfolio of products and services, including SGK1 Inhibitors and THRV-1268. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Inhibitors for treating heart conditions like LQTS and heart failure.
Novel inhibitor for heart failure and atrial fibrillation treatments.
Funding Insights of Thryv Therapeutics
Thryv Therapeutics has successfully raised a total of $24M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $5 million completed in June 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series A — $5.0M
-
First Round
First Round
(10 Aug 2021)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2023 | Amount | Series A - Thryv Therapeutics | Valuation | Invest Quebec |
|
| Jan, 2022 | Amount | Grant - Thryv Therapeutics | Valuation |
investors |
|
| Aug, 2021 | Amount | Series A - Thryv Therapeutics | Valuation | Amplitude , Lumira Ventures |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Thryv Therapeutics
Thryv Therapeutics has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include ARE, EJP RD and Invest Quebec. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are made in precision medicine companies.
|
Founded Year | Domain | Location | |
|
Lumira Ventures is engaged in life sciences venture capital investment.
|
Founded Year | Domain | Location | |
|
Amzak Health is engaged in venture investments in life sciences.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Thryv Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Thryv Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Thryv Therapeutics Comparisons
Competitors of Thryv Therapeutics
Thryv Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Incyte and argenx, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment.
|
|
| domain | founded_year | HQ Location |
Antibodies are developed for treating cancer, eye, and inflammatory diseases.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Thryv Therapeutics
Frequently Asked Questions about Thryv Therapeutics
When was Thryv Therapeutics founded?
Thryv Therapeutics was founded in 2018 and raised its 1st funding round 3 years after it was founded.
Where is Thryv Therapeutics located?
Thryv Therapeutics is headquartered in Montreal, Canada. It is registered at Montreal, Quebec, Canada.
Who is the current CEO of Thryv Therapeutics?
Paul F Truex is the current CEO of Thryv Therapeutics.
Is Thryv Therapeutics a funded company?
Thryv Therapeutics is a funded company, having raised a total of $24M across 3 funding rounds to date. The company's 1st funding round was a Series A of $19M, raised on Aug 10, 2021.
What does Thryv Therapeutics do?
Thryv Therapeutics provider of therapy services for rare diseases, focusing on life sciences, cardiac and vascular disorders, drugs, and diversified. It serves clients with dedicated solutions, emphasizing quality, innovation, and sustainable growth in its core markets. It continues to evolve, meeting industry challenges with strategic approaches.
Who are the top competitors of Thryv Therapeutics?
Thryv Therapeutics's top competitors include Moderna, Jazz Pharmaceuticals and argenx.
What products or services does Thryv Therapeutics offer?
Thryv Therapeutics offers SGK1 Inhibitors and THRV-1268.
Who are Thryv Therapeutics's investors?
Thryv Therapeutics has 7 investors. Key investors include ARE, EJP RD, Invest Quebec, Amplitude Ventures, and Lumira Ventures.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.